Get started
Gossamer Bio, Inc.Gossamer Bio, Inc.Gossamer Bio, Inc.

Gossamer Bio, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

GOSS chart


Full chart

GOSS upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪157.63 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.3178 USD
Net income (FY)
‪−179.82 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪173.94 M‬
Beta (1Y)
1.48

Employees


Employees (FY)
135
Change (1Y)
−43 −24.16%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−1.33 M‬ USD

About Gossamer Bio, Inc.


Sector
Health Technology
CEO
Faheem Hasnain
Headquarters
San Diego
Website
gossamerbio.com
Founded
2015
FIGI
BBG00MVWLLM2
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

GOSS news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

GOSS highest yielding bonds


GOSS4989769
Gossamer Bio, Inc. 5.0% 01-JUN-2027
Yield to maturity
40.23%
Maturity date
Jun 1, 2027

Explore more bonds 

Frequently Asked Questions


The current price of GOSS is 0.6956 USD — it has increased by 4.66% in the past 24 hours. Watch Gossamer Bio, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Gossamer Bio, Inc. stocks are traded under the ticker GOSS.
GOSS stock has fallen by −8.67% compared to the previous week, the month change is a −22.71% fall, over the last year Gossamer Bio, Inc. has showed a −11.39% decrease.
We've gathered analysts' opinions on Gossamer Bio, Inc. future price: according to them, GOSS price has a max estimate of 15.00 USD and a min estimate of 0.50 USD. Watch GOSS chart and read a more detailed Gossamer Bio, Inc. stock forecast: see what analysts think of Gossamer Bio, Inc. and suggest that you do with its stocks.
GOSS reached its all-time high on Dec 12, 2019 with the price of 27.1497 USD, and its all-time low was 0.4525 USD and was reached on Oct 24, 2023. View more price dynamics on GOSS chart.
See other stocks reaching their highest and lowest prices.
GOSS stock is 7.30% volatile and has beta coefficient of 1.48. Track Gossamer Bio, Inc. stock price on the chart and check out the list of the most volatile stocks — is Gossamer Bio, Inc. there?
Today Gossamer Bio, Inc. has the market capitalization of ‪157.63 M‬, it has decreased by −10.20% over the last week.
Yes, you can track Gossamer Bio, Inc. financials in yearly and quarterly reports right on TradingView.
Gossamer Bio, Inc. is going to release the next earnings report on Mar 21, 2025. Keep track of upcoming events with our Earnings Calendar.
GOSS earnings for the last quarter are −0.14 USD per share, whereas the estimation was −0.15 USD resulting in a 4.86% surprise. The estimated earnings for the next quarter are −0.17 USD per share. See more details about Gossamer Bio, Inc. earnings.
Gossamer Bio, Inc. revenue for the last quarter amounts to ‪9.48 M‬ USD, despite the estimated figure of ‪8.53 M‬ USD. In the next quarter, revenue is expected to reach ‪7.02 M‬ USD.
GOSS net income for the last quarter is ‪−30.80 M‬ USD, while the quarter before that showed ‪49.23 M‬ USD of net income which accounts for −162.57% change. Track more Gossamer Bio, Inc. financial stats to get the full picture.
No, GOSS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 24, 2024, the company has 135.00 employees. See our rating of the largest employees — is Gossamer Bio, Inc. on this list?
Like other stocks, GOSS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Gossamer Bio, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Gossamer Bio, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Gossamer Bio, Inc. stock shows the sell signal. See more of Gossamer Bio, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.